Author(s):
Pranab Moudgil, Sangita Mishra, Lekha S, Vinni Kalra, M P Venkatesh
Email(s):
venkateshmpv@jssuni.edu.in
DOI:
10.52711/0975-4377.2026.00031 
Address:
Pranab Moudgil1, Sangita Mishra1, Lekha S1, Vinni Kalra2, M P Venkatesh1,3*
1Centre of Excellence in Regulatory Sciences, Dept. of Pharmaceutics, JSS College of Pharmacy, JSSAHER, Mysuru 570015, Karnataka, India.
2Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala 147002, Punjab, India.
3Faculty of Pharmaceutical Sciences, UCSI University, Malaysia.
*Corresponding Author
Published In:
Volume - 18,
Issue - 3,
Year - 2026
ABSTRACT:
Modified-release (MR) drug delivery systems offer precise spatiotemporal control of drug exposure, allowing for alignment with interindividual pharmacokinetic (PK) and pharmacodynamic (PD) variability, and addressing the fundamental shortcomings of conventional fixed-dose therapies in chronic disease management. This narrative review critically examines recent advances in MR platforms, including stimuli-responsive systems and advanced nanocarriers that enable patient-centric customization based on age, physiological status, genetic variability, and comorbidity profiles. The integration of MR formulation design with quantitative clinical pharmacology tools, such as model-informed precision dosing (MIPD), physiologically based pharmacokinetic (PBPK) modeling, and in vitro–in vivo correlation (IVIVC), is highlighted as a key strategy for enhancing translational predictability, optimizing therapeutic performance, and facilitating regulatory acceptance. Emerging manufacturing technologies, particularly three-dimensional (3D) printing, are discussed as disruptive enablers of on-demand, patient-specific MR dosage forms, with growing evidence of clinical and operational feasibility in pediatric populations and complex treatment regimens. Furthermore, the convergence of digital patient twins (DPTs), real-time clinical data streams, and adaptive analytics is positioned as a transformative paradigm for dynamically optimized therapies. Collectively, these developments establish an integrated framework for MR-enabled personalized medicine, supporting the rational design and scalable implementation of individualized therapeutic strategies for chronic diseases requiring long-term pharmacological intervention.
Cite this article:
Pranab Moudgil, Sangita Mishra, Lekha S, Vinni Kalra, M P Venkatesh. Integrating Modified-Release Systems with Personalized Medicine: A Salient Framework for Disease Management. Research Journal of Pharmaceutical Dosage Forms and Technology.2026; 18(3):209-6. doi: 10.52711/0975-4377.2026.00031
Cite(Electronic):
Pranab Moudgil, Sangita Mishra, Lekha S, Vinni Kalra, M P Venkatesh. Integrating Modified-Release Systems with Personalized Medicine: A Salient Framework for Disease Management. Research Journal of Pharmaceutical Dosage Forms and Technology.2026; 18(3):209-6. doi: 10.52711/0975-4377.2026.00031 Available on: https://rjpdft.com/AbstractView.aspx?PID=2026-18-3-6
6. REFERENCES:
1. Swapnaa B, Kumar SV. Personalized medicine-A novel approach in cancer therapy. Research Journal of Pharmacy and Technology. 2017; 10(1): 341. doi: 10.5958/0974-360X.2017.00069.5
2. Rahul Khiste, Nilkanth Bhapkar, Nilesh Kulkarni. A Review on Applications of Hydroxy Propyl Methyl Cellulose and Natural polymers for the development of modified release drug delivery systems. Research Journal of Pharmacy and Technology. 2021; 14(2): 1163-1170. doi: 10.5958/0974-360X.2021.00208.0
3. Darwich AS, Ogungbenr K, Hatley OJ, Rostami-Hodjegan A. Role of pharmacokinetic modeling and simulation in precision dosing of anticancer drugs. Transl Cancer Res. 2017 Dec; 6(S10): S1512–29
4. Romley JA, Xie Z, Chiou T, Goldman D, Peters AL. Extended-release formulation and medication adherence. Journal of General Internal Medicine. 2020 Jan; 35(1): 354-6. doi: 10.1007/s11606-019-05275-1
5. Djuris J, Cvijic S, Djekic L. Model-informed drug development: in silico assessment of drug bioperformance following oral and percutaneous administration. Pharmaceuticals. 2024 Jan 30; 17(2): 177. doi: 10.3390/ph17020177
6. Grzegorzewski J, Brandhorst J, Green K, Eleftheriadou D, Duport Y, Barthorscht F, Köller A, Ke DY, De Angelis S, König M. PK-DB: pharmacokinetics database for individualized and stratified computational modeling. Nucleic Acids Research. 2021 Jan 8; 49(D1): D1358-64. doi: 10.1093/nar/gkaa990
7. Fischer RP, Volpert A, Antonino P, Ahrens TD. Digital patient twins for personalized therapeutics and pharmaceutical manufacturing. Frontiers in Digital Health. 2024 Jan 5; 5: 1302338. doi: 10.3389/fdgth.2023.1302338
8. Bachhav R, Bachhav P, Deore R, Sonawane G, Surana K, Mahajan S. Biodegradable Polymers in Drug Delivery: A Detailed Review. Asian Journal of Pharmaceutical Research. 2025 May 5; 153–8. doi: 10.52711/2231-5691.2025.00025
9. Mankar SD, Kale C, Kanchan J. 3D printing technology-A computer aided Design-A review. Research Journal of Science and Technology. 2019 Jul 1; 11(3): 217-24. doi: 10.5958/2349-2988.2019.00032.9
10. Hemanth KG, Hemamanjushree S, Abhinaya N, Pai R, Girish KP. 3D printing: A review on technology, role in novel dosage forms and regulatory perspective. Research Journal of Pharmacy and Technology. 2021; 14(1): 562-72. doi: 10.5958/0974-360X.2021.00102.5
11. Marques L, Costa B, Pereira M, Silva A, Santos J, Saldanha L, Silva I, Magalhães P, Schmidt S, Vale N. Advancing precision medicine: a review of innovative in silico approaches for drug development, clinical pharmacology and personalized healthcare. Pharmaceutics. 2024 Feb 27; 16(3): 332. doi: 10.3390/ pharmaceutics16030332
12. Patel R, Patel A. In vivo–In Vitro correlation (IVIVC) in drug development: bridging preclinical and clinical outcomes for regulatory approvals. World Journal of Advanced Research and Reviews. 2024 May 30; 22(2): 2311-28. doi: 10.30574/ wjarr.2024.22.2.1197
13. Mukherjee S, Joshi V, Reddy KP, Singh N, Das P, Datta P. Biopharmaceutical and pharmacokinetic attributes to drive nanoformulations of small molecule tyrosine kinase inhibitors. Asian Journal of Pharmaceutical Sciences. 2024 Dec 1; 19(6): 100980. doi: 10.1016/j.ajps.2024.100980
14. Da Rocha JE, Othman H, Botha G, Cottino L, Twesigomwe D, Ahmed S, Drögemöller BI, Fadlelmola FM, Machanick P, Mbiyavanga M, Panji S. The extent and impact of variation in ADME genes in sub-Saharan African populations. Frontiers in Pharmacology. 2021 Apr 28; 12: 634016. doi: 10.3389/ fphar.2021.634016
15. Yogesh S. Purkar, Rajendra K. Surawase. Overview: A Novel Approach on Extended-Release Tablet. Research Journal of Pharmaceutical Dosage Forms and Technology. 2024; 16(2): 183-8. doi: 10.52711/0975-4377.2024.00029
16. Drummond D, Gonsard A. Definitions and characteristics of patient digital twins being developed for clinical use: scoping review. Journal of Medical Internet Research. 2024 Nov 13; 26: e58504. doi: 10.2196/58504
17. Center for Drug Evaluation and Research. U.S. Food and Drug Administration. 2025. Orange Book Data Files. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
18. Venkatesh KP, Brito G, Kamel Boulos MN. Health Digital Twins in Life Science and Health Care Innovation. Annu Rev Pharmacol Toxicol. 2024 Jan 23; 64(1): 159–70. doi: 10.1146/annurev-pharmtox-022123-022046
19. Henriksen AP, Rodríguez CL, Currant H, Louloudis I, Biel JH, Herrero-Zazo M, Birney E, Hansen TF, Mazzoni G, Haue AD, Bundgaard H. Genome-wide associations spanning 194 in-hospital drug dosage change phenotypes highlight diverse genetic backgrounds in concurrent drug therapy. Computational and Structural Biotechnology Journal. 2025 Jan 1; 28: 239-48. doi: 10.1016/j.csbj.2025.06.042
20. Maharjan R, Kim NA, Kim KH, Jeong SH. Transformative roles of digital twins from drug discovery to continuous manufacturing: pharmaceutical and biopharmaceutical perspectives. Int J Pharm X. 2025 Dec; 10: 100409. doi: 10.1016/j.ijpx.2025.100409
21. Prajapati SK, Jain A, Jain A, Jain S. Biodegradable polymers and constructs: A novel approach in drug delivery. European Polymer Journal. 2019 Nov 1; 120: 109191. doi: 10.1016/ j.eurpolymj.2019.08.018
22. Sushant M. Ahire, Prerana S. Pawar, Vijayraj N. Sonawane, Shivraj P. Jadhav. Personalized Medicine and Pharmacogenomics: Impact of Genetic variation on Drug Response and Individualized Therapy - A Review. Asian Journal of Pharmacy and Technology. 2026; 16(1): 91-8. doi: 10.52711/2231-5713.2026.00013
23. Dean L. Irinotecan Therapy and UGT1A1 Genotype. 2015 May 27 [Updated 2018 Apr 4]. In: Pratt VM, Scott SA, Pirmohamed M, et al., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-, available on https://www.ncbi.nlm.nih.gov/books/NBK294473/
24. Melnyk LA, Oyewumi MO. Integration of 3D printing technology in pharmaceutical compounding: Progress, prospects, and challenges. Annals of 3D Printed Medicine. 2021 Dec 1; 4: 100035. doi: 10.1016/j.stlm.2021.100035
25. Lipska KJ, Bailey CJ, Inzucchi SE. Use of Metformin in the Setting of Mild-to-Moderate Renal Insufficiency. Diabetes Care. 2011 Jun 1; 34(6): 1431–7. doi: 10.2337/dc10-2361
26. Englezos K, Wang L, Tan ECK, Kang L. 3D printing for personalised medicines: implications for policy and practice. Int J Pharm. 2023 Mar; 635: 122785. doi: 10.1016/ j.ijpharm.2023.122785
27. Abd Elaziz M, Al‐qaness MA, Dahou A, Al‐Betar MA, Mohamed MM, El‐Shinawi M, Ali A, Ewees AA. Digital twins in healthcare: Applications, technologies, simulations, and future trends. Wiley Interdisciplinary Reviews: Data Mining and Knowledge Discovery. 2024 Nov; 14(6): e1559. doi: 10.1002/widm.1559
28. Katsoulakis E, Wang Q, Wu H, Shahriyari L, Fletcher R, Liu J, Achenie L, Liu H, Jackson P, Xiao Y, Syeda-Mahmood T. Digital twins for health: a scoping review. NPJ Digital Medicine. 2024 Mar 22; 7(1): 77. doi: 10.1038/s41746-024-01073-0
29. Ferreira R. Understanding Pharmacokinetic Variability: Implications for Therapy. Journal of Pharmacokinetics & Experimental Therapeutics. 2024 Jun 28; 8(3). doi: 10.4172/ jpet.1000248
30. P. V. Kamala Kumari, Y. Srinivasa Rao. Personalized Medicine- A Review. Research Journal of Pharmacy and Technology 2019; 12(8): 3989-3992. doi: 10.5958/0974-360X.2019.00687.5
31. Ng K, Kartoun U, Stavropoulos H, Zambrano JA, Tang PC. Personalized treatment options for chronic diseases using precision cohort analytics. Scientific Reports. 2021 Jan 13; 11(1): 1139. doi: 10.1038/s41598-021-80967-5
32. Minichmayr IK, Dreesen E, Centanni M, Wang Z, Hoffert Y, Friberg LE, Wicha SG. Model-informed precision dosing: state of the art and future perspectives. Advanced Drug Delivery Reviews. 2024 Dec 1; 215: 115421. doi: 10.1016/j.addr.2024.115421
33. Hetvi Pastagia, Anuradha Prajapati, Bhoomi S. Patel, Sachin B. Narkhede, Shailesh Luhar, Sakshi Dineshbhai Tandel. Personalized Medicine: Advancing Precision Medicine used in Autoinflammatory and Related Disorders. Asian Journal of Pharmaceutical Analysis. 2026; 16(1): 34-0. doi: 10.52711/2231-5675.2026.00006
34. Tanaka R. Pharmacokinetic variability and significance of therapeutic drug monitoring for broad-spectrum antimicrobials in critically ill patients. J Pharm Health Care Sci. 2025 Mar 17; 11(1): 21. doi: 10.1186/s40780-025-00425-6
35. Revel J and Gorria P, Modified-Release Formulations: Improving Efficacy and Patient Compliance, Solid Dosage Drug Development and Manufacturing Supplement. 2020 April: s6-s8.
36. Fernandes JB, Teixeira F, Godinho C. Personalized care and treatment compliance in chronic conditions. Journal of Personalized Medicine. 2022 May 1; 12(5): 737. doi: 10.3390/ jpm12050737
37. Zhu B, Zhu Y, Chen D, Jin P. Therapeutic drug monitoring for promotion of rational medication in the elderly: Overview, challenges and opportunities. Precision Medication. 2024 Nov; 1(1): 100006. doi: 10.1016/j.prmedi.2024.10.006
38. Saba Wahid Khan, Indira Parab. A Detailed Review on 3D Bioprinting and it's Application in Pharmaceutical Science. International Journal of Technology. 2023; 13(1): 57-7. doi: 10.52711/2231-3915.2023.00007
39. Akiladevi D, Raman Suresh Kumar, Arunkumar N. A Review on 3D printing Pharmaceutical Manufacturing and applications on Drug Delivery System. Research Journal of Pharmacy and Technology 2019; 12(2): 873-875. doi: 10.5958/0974-360X.2019.00149.5
40. N. Madhavi, A. Nikitha, M. Sreeja, T. Rama Rao. A Review on 3D Printing Technology: Personalized Medicine for Special Population. Research Journal of Pharmaceutical Dosage Forms and Technology. 2025; 17(2): 137-42. doi: 10.52711/0975-4377.2025.00020
41. Chu X, Ye Y, Tang S, Han M, Wang G, Lin S, Sun B, Huang Q, Zhang Y, Chu X, Bao K. Personalized Medication for Chronic Diseases Using Multimodal Data‐Driven Chain‐of‐Decisions. Advanced Science. 2025 Oct; 12(40): e04079. doi: 10.1002/ advs.202504079
42. Yao Y, Zhang L, Chen D, Qin S, Meng M, Guo Q. Global research on the utilization of population pharmacokinetic model: a bibliometric analysis from 2000 to 2024. Frontiers in Pharmacology. 2025 May 12; 16: 1548023. doi: 10.3389/ fphar.2025.1548023
43. Awad A, Goyanes A, Basit AW, Zidan AS, Xu C, Li W, Narayan RJ, Chen RK. A review of state-of-the-art on enabling additive manufacturing processes for precision medicine. Journal of Manufacturing Science and Engineering. 2023 Jan 1; 145(1): 010802. doi: 10.1115/1.4056199
44. Su J, Yang L, Sun Z, Zhan X. Personalized Drug Therapy: Innovative Concept Guided With Proteoformics. Molecular & Cellular Proteomics. 2024 Mar; 23(3): 100737. Doi: 10.1016/j.mcpro.2024.100737
45. Scott K. The Role of Therapeutic Drug Monitoring in Managing Drug Response Variability. Journal of Applied Pharmacy. 2024; 16(3). doi: 10.35248/1920-4159.24.16.427
46. Beaumont C, Young GC, Cavalier T, Young MA. Human absorption, distribution, metabolism and excretion properties of drug molecules: a plethora of approaches. British Journal of Clinical Pharmacology. 2014 Dec; 78(6): 1185-200. doi: 10.1111/bcp.12468
47. Rashmi Shah. Pharmacokinetics: Drug absorption, distribution, metabolism, and excretion (ADME). Pharma Innovation 2019; 8(1): 865-869. doi: 10.22271/tpi.2019.v8.i1n.25492
48. Ferrell PB, McLeod HL. Carbamazepine, HLA-B*1502 and Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: US FDA Recommendations. Pharmacogenomics. 2008 Oct 14; 9(10): 1543–6. doi: 10.2217/14622416.9.10.1543
49. Dean L. Carbamazepine Therapy and HLA Genotype. In: Medical Genetics Summaries. National Center for Biotechnology Information (US), Bethesda (MD); 2012, available on https://europepmc.org/article/nbk/nbk321445#free-full-text
50. Joković D, Milosavljević F, Stojanović Z, Šupić G, Vojvodić D, Uzelac B, Jukić MM, Ćurčin AP. CYP2C19 slow metabolizer phenotype is associated with lower antidepressant efficacy and tolerability. Psychiatry Research. 2022 Jun 1; 312: 114535. doi: 10.1016/j.psychres.2022.114535
51. Díaz-Santiago E, Moya-García AA, Pérez-García J, Yahyaoui R, Orengo C, Pazos F, Perkins JR, Ranea JA. Better understanding the phenotypic effects of drugs through shared targets in genetic disease networks. Frontiers in Pharmacology. 2025 Jan 22; 15: 1470931. doi: 10.3389/fphar.2024.1470931
52. McLachlan AJ, Pont LG. Drug metabolism in older people—a key consideration in achieving optimal outcomes with medicines. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences. 2012 Feb 1; 67(2): 175-80. doi: 10.1093/gerona/ glr118
53. Mealey KL, Martinez SE, Villarino NF, Court MH. Personalized medicine: going to the dogs?. Human Genetics. 2019 May 1; 138(5): 467-81. doi: 10.1007/s00439-019-02020-w
54. Culliford R, Lawrence SE, Mills C, Tippu Z, Chubb D, Cornish AJ, Browning L, Kinnersley B, Bentham R, Sud A, Pallikonda H. Whole genome sequencing refines stratification and therapy of patients with clear cell renal cell carcinoma. Nature Communications. 2024 Jul 15; 15(1): 5935. doi: 10.1038/s41467-024-49692-1
55. Khan D, Kirby D, Bryson S, Shah M, Mohammed AR. Paediatric specific dosage forms: Patient and formulation considerations. International Journal of Pharmaceutics. 2022 Mar 25; 616: 121501. doi: 10.1016/j.ijpharm.2022.121501
56. Jørgensen AK, Goyanes A, Basit AW. Entering new domains for 3D printing of drug products. Pharm Technol. 2025 Apr; 49(3): 24-7.
57. Mbah Cornelius Abuchi, Isaac Ndukwe Egbe, Nwaume Emeka Joseph, Ikeyi Adachukwu Pauline, Abah Evelyn Ifeoma, et al. (2025) From Infancy to Frailty: Age and Disease-Linked Modulation of Drug Metabolism. J Pharmacol Drug Metab 8: 1-15
58. Vrbanac J, Slauter R. ADME in drug discovery. In A Comprehensive Guide to Toxicology in Nonclinical Drug Development. 2017 Jan 1 (pp. 39-67). Academic Press.
59. Ngcobo NN. Influence of Ageing on the Pharmacodynamics and Pharmacokinetics of Chronically Administered Medicines in Geriatric Patients: A Review. Clinical Pharmacokinetics. 2025 Mar; 64(3): 335-67. doi: 10.1007/s40262-024-01466-0
60. Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Advanced Drug Delivery Reviews. 2012 Dec 1; 64: 163-74. doi: 10.1016/j.addr.2012.09.028
61. Food-Effect Bioavailability and Fed Bioequivalence Studies. U.S. Food and Drug Administration. U.S. Department of Health and Human Services; December 2002, available on https://www.fda.gov/files/drugs/published/Food-Effect-Bioavailability-and-Fed-Bioequivalence-Studies.pdf
62. Zhang W, Zhang Q, Cao Z, Zheng L, Hu W. Physiologically Based Pharmacokinetic Modeling in Neonates: Current Status and Future Perspectives. Pharmaceutics. 2023 Dec 12; 15(12): 2765. doi: 10.3390/pharmaceutics15122765
63. Wang Y, Otte A, Park H, Park K. In vitro-in vivo correlation (IVIVC) development for long-acting injectable drug products based on poly(lactide-co-glycolide). Journal of Controlled Release. 2025 Jan; 377: 186–96. doi: 10.1016/j.jconrel.2024.11.021
64. Sirisha S. A review on ivivc in the development of oral drug formulation: Data obtained from past two decades. Research Journal of Pharmaceutical Dosage Forms and Technology. 2020 Jul 1; 12(3): 198-204. doi: 10.5958/0975-4377.2020.00034.8
65. Madabushi R, Seo P, Zhao L, Tegenge M, Zhu H. Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making: Madabushi et al. Pharmaceutical Research. 2022 Aug; 39(8): 1669-80. doi: 10.1007/s11095-022-03288-w
66. Technical Considerations for Additive Manufactured Medical Devices. U.S. Food and Drug Administration. 2017, available on https://www.fda.gov/files/medical%20devices/published/Technical-Considerations-for-Additive-Manufactured-Medical-Devices---Guidance-for-Industry-and-Food-and-Drug-Administration-Staff.pdf
67. Guideline on quality of oral modified release products. European Medicines Agency. 2014. p. 1–16, available on https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-oral-modified-release-products_en.pdf
68. Hilmer SN, Gazarian M. Clinical pharmacology in special populations: the extremes of age. Expert Review of Clinical Pharmacology. 2008 Jul 1; 1(4): 467-9. doi: 10.1586/ 17512433.1.4.467
69. Chen ML, Shah VP, Ganes D, Midha KK, Caro J, Nambiar P, Rocci Jr ML, Thombre AG, Abrahamsson B, Conner D, Davit B. Challenges and opportunities in establishing scientific and regulatory standards for assuring therapeutic equivalence of modified release products: workshop summary report. The AAPS Journal. 2010 Sep; 12(3): 371-7. doi: 10.1208/s12248-010-9201-5
70. Jamalinia M, Weiskirchen R. Advances in personalized medicine: Translating genomic insights into targeted therapies for cancer treatment. Annals of Translational Medicine. 2025 Apr 30; 13(2): 18. doi: 10.21037/atm-25-34
71. Grogan S, Preuss CV. Pharmacokinetics. [Updated 2023 Jul 30]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-, available on https://www.ncbi.nlm.nih.gov/ books/NBK557744/
72. Ernstmeyer K, Christman E, editors. Nursing Pharmacology [Internet]. 2nd edition. Eau Claire (WI): Chippewa Valley Technical College; 2023. Chapter 1 Pharmacokinetics & Pharmacodynamics, available on https://www.ncbi.nlm.nih.gov/ books/NBK595006/
73. Drummond D, Gonsard A. Definitions and characteristics of patient digital twins being developed for clinical use: scoping review. Journal of Medical Internet Research. 2024 Nov 13; 26: e58504. doi: 10.2196/58504
74. Viviani R, Berres J, Stingl JC. Phenotypic Models of Drug–Drug‐Gene Interactions Mediated by Cytochrome Drug‐Metabolizing Enzymes. Clinical Pharmacology & Therapeutics. 2024 Sep; 116(3): 592-601. doi: 10.1002/cpt.3188
75. Jadhav NR, Patil A, Karne HU, Soni SL. Advances in Biodegradable Polymer-based Drug Delivery Systems. Journal of Polymer and Composites. 2025; 13(4): 326–38.
76. Jørgensen AK, Griffen J, Wills R, Parhizkar M, Goyanes A, Basit AW. Enabling Personalised 3D Printed Extended-Release Oral Drug Products: Transmission Raman Spectroscopy as a Rapid Quality Control Tool. European Journal of Pharmaceutical Sciences. 2025 Oct 20: 107341. doi: 10.1016/j.ejps.2025.107341